Debiopharm Group (Debiopharm) is a family-owned biopharmaceutical group of companies headquartered in Lausanne, Switzerland. It was founded in 1979 by Rolland-Yves Mauvernay. The group works through its subsidiaries: As of 2010 two drugs had reached the market through its efforts: oxaliplatin for the treatment of cancer, and depot formulations of triptorelin, a gonadotropin-releasing hormone agonist that is used to treat prostate cancer and pedophilia in men, and in women, breast cancer, ovarian cancer, endometriosis, uterine fibromyomas, precocious puberty, and female infertility.